Objectives: Previous research has suggested that sodium citrate improves hyposmia by decreasing mucus calcium levels in the nose. This study aimed to confirm or refute this effect in a single application and assess potential side-effects.
synthesis of cAMP by adenylyl cyclase. The rise in intracellular cAMP leads to the opening of cyclic nucleotide-gated (CNG) channels and an influx of Na + and Ca 2+ , which eventually may lead to axonal firing.
Calcium plays a key, conflicting, role in the responses of the olfactory receptor cells. It acts both as an excitatory second messenger to increase the magnitude of receptor current but also as an inhibitory messenger important in response termination but adaptation. It is well established that cytoplasmic Ca 2+ regulates sensitivity to cAMP. 4, 5 By entering the cilium during the odorant response, Ca 2+ reduces the sensitivity of CNG channels to cAMP. 6 A rise in mucosal Ca 2+ through the above-described mechanism increases negative feedback on the olfactory pathway ultimately reducing sensitivity to odorant stimulus. In the normosmic patient, this provides a mechanism for long-term odour adaptation. It is therefore possible that in the patients with olfactory loss, reducing mucosal Ca 2+ levels may reduce the negative feedback, which in these circumstances may contribute to their anosmia/hyposmia. This effect is supported by an animal study that found prolonged olfactory stimulation in frog olfactory receptor cells when creating a similar environment. 5, 7 Modulation of calcium concentrations in the olfactory environment would therefore certainly be an attractive target for pharmacologic intervention in humans, with an established underlying physiological basis.
Sodium citrate, a solution licensed and used safely in other body cavities (eg, stomach and bladder), is known to buffer calcium ions, leading to a reduction in mucosal Ca 2+ and subsequent reduction in negative feedback. A previous study by Panagiotopoulos et al. 8 has
suggested that the application of sodium citrate improves hyposmia by decreasing mucus calcium levels in the nose. On the basis of the above physiological rationale, reduction in free Ca 2+ ions is likely to increase the excitability of olfactory neurons, thus improving the sense of smell. The sodium citrate solution douched in the nose should have the effect of binding free calcium ions in the nasal mucus, thus reducing mucosal calcium. The Panagiotopoulos study did, however, have certain limitations including the small number of participants and the method of application as well as the use of an identification test as the main assessment of olfactory performance.
| Objectives
Primary objective: To measure the effect of sodium citrate nasal spray on short-term olfactory performance compared to placebo.
Secondary objectives: To determine the acceptability of sodium citrate nasal spray as a treatment for olfactory disorders.
| MATERIALS AND METHODS

| Ethical approval and funding
Ethical approval was sought and obtained from the Eastern Multicen- 
| Trial design
The study was conducted as a randomised double-blind controlled trial recruiting 55 patients who met criteria below.
| Participants
Patients referred to a tertiary Smell & Taste Disorders clinic were assessed for eligibility and approached by the lead author. Basic demographic data including age and sex were collected.
| Inclusion criteria
• All patients with non-conductive olfactory disorders (NCODs) as confirmed by history and examination.
| Exclusion criteria
• Patients with any endoscopic findings of conductive loss including chronic rhinosinusitis with/without nasal polyposis and severe nasal septal deviation (preventing passage of 4-mm endoscope).
• Patients with congenital anosmia.
• Patients with any inhalant allergies.
• Patients with asthma.
• Children under the age of 16.
All patients provided written informed consent after the aims and methods of the study had been described to them and after they had received an information sheet.
| Interventions
Participants were randomly allocated to one of two groups. In the treatment arm, participants were sprayed with 1 mL of 9% sodium citrate solution; 0.5 mL to each side of the nose.
Keypoints
• Intranasal sodium citrate appears to have a beneficial but transitory effect on human olfaction.
• Longer term data is needed to further support the role of topical intranasal citrate in treating olfactory disorders.
• Local side-effects were evident but well tolerated by subjects.
Participants in the control arm received the corresponding volume of sterile water. The solution was applied using a nozzle adapted to target the olfactory cleft ( Figure 1 ) as can be found on other nasal spray kits such as co-phenylcaine; the nozzle was manipulated to point upwards prior to insertion into the nose. 
| Secondary outcome measures
• Best improvement in olfactory threshold compared to baseline for all odours as defined by a threshold shift of at least more than one in the direction of the weaker odour concentration.
• Number of individuals who responded (for those individuals who responded, we also recorded the time until best improvement).
• Adverse events
Subjects underwent a series of threshold smell tests using the phenyl ethyl alcohol (roses), 1-butanol (pear), acetic acid (vinegar) and eucalyptol (menthol) on the basis of previous work by the senior authors 9 and in conjunction with accepted threshold testing formats previously validated. 10,11 A 50 mL volume of each of four odours in 250-mL bottles was arranged in seven 10-fold dilutions from 10 À1 to 10 À7 for 1-butanol, acetic acid and eucalyptol and 10 À2 to 10 À8 for phenyl alcohol. At the beginning of the trial, the odour mercaptan was used but was subsequently replaced with 1-butanol due to the need to replenish the odour solutions more frequently than the others and was deemed an unreliable test odour.
The format of the test had been fully explained to the subject beforehand by the research nurse who tested the patient. This format of olfactory testing was chosen as it would allow for quicker reassessment at repeat intervals compared to a full Sniffin' Sticks test battery, but would provide a more accurate assessment of olfactory performance than an identification only test. 12 The subject was then started with the smallest concentration of each odour and with sterile water for comparison, ascended through the odour concentrations in a forced response format until they correctly detected the odour as distinct from the sterile water. 10 Once the subject had correctly identified two concentrations of a single odour in a row, the weaker concentration of the odour detected was taken as their threshold and recorded. This was then repeated for the remaining three odours, and the four thresholds obtained were considered the baseline olfactory performance. The format of the test had been fully explained to the subject beforehand by the research nurse who tested the patient. 10, 12 After application of the intervention, the olfactory threshold tests to the four odours were then repeated every 15 minutes up to a maximum of 120 minutes. At each 15-minute interval, patients were started two places below their previous threshold to avoid unnecessary extra steps. The maximum change in threshold was recorded for each odour, as was the duration of any effect if seen. If no improvement was noted for all four odours by 60 minutes then further testing was abandoned.
At the end of the trial, participants were asked to report any adverse effects from the spray they had received.
| Sample size
To detect a moderate-to-large Cohen's effect size of 0.75 (mean difference/standard deviation of the difference), at 80% power at the 5% level of significance, would need 30 patients in each arm.
| Randomisation 2.7.1 | Sequence generation, allocation concealment and implementation
The code randomisation sequence was computer generated, and coded bottles of solution were provided to researchers who had no knowledge of the contents of each bottle. The random sequence was generated by Microsoft Excel number randomiser generator in the hospital pharmacy who assigned enrolled participants to the intervention. Once the participant agreed to be in the study, the study nurse phoned the pharmacy who then provided a coded bottle to use in the clinic. 
| Statistical methods
The analysis included all randomised individuals who had valid outcome measurements. The primary analysis compared the best improvement with the PEA odour between control and intervention groups using a Mann-Whitney test as the outcome was not normally distributed. The same analysis was also performed separately for each odour tested for the best improvement and the duration.
Response to treatment, defined by a difference of at least two thresholds, was tested using a chi-squared test. We considered P≤.05 as significant, and all statistical analyses were conducted using Stata 14.0/SE.
3 | RESULTS
| Participant flow
A total of 98 patients were assessed for eligibility and after exclusion or declining, 61 participants were randomised, with 31 allocated to the treatment arm and 30 to the control arm, but four participants did not attend their appointment on the day and two did not complete the sequence of testing after application (see Figure 2 ). The trial ran from October 2007 to December 2014 and stopped when the target sample size had been recruited.
| Baseline data
Female participants accounted for 76% of those in the trial with an age range of 20 to 79 (mean of 53) in all subjects. The underlying diagnoses were post-viral olfactory loss (26, 42%), post-traumatic olfactory loss (9, 16%) and idiopathic (20, 36%). On psychophysical olfactory testing (using the Sniffin' Sticks), 29 (52%) were functionally anosmic and 17 (30%) were hyposmic; the TDI score was irretrievable for two subjects and not performed in seven subjects. The balance of the two treatment arms is shown in Table 1 , and it can be seen that there is some difference between the groups in terms of gender and diagnosis.
| Numbers analysed
As participation in the trial only required one visit and one intervention, all participants completed the trial once randomised except for four in the control arm who failed to attend the study visit and a further two that failed to complete the sequence of tests on the study visit. Due to the small number of participants that had been tested with mercaptan (7), no specific analysis of these data was undertaken.
| Outcomes and estimation
Based on a best improvement in thresholds (logarithmic concentration being lower than baseline), there were significant differences between the intervention and control groups (P<.05) for all odours except for ACA (Table 2a) . Based on a clinically significant shift in thresholds of two or more, 10 participants responded to PEA, 10 to 1-BUT, nine to ACA and nine to EUC; again, these were clinically significant for 1-BUT and EUC and approaching significance for PEA (Table 2b ). In seven patients who were evaluated with mercaptan instead of 1-butanol, four hyposmic patients (out of the seven)
showed a positive threshold shift of ≥2 places in response to citrate. Table 3 shows the proportions of anosmic and hyposmic patients demonstrating that baseline olfactory performance does not necessarily appear to be a reliable indicator of potential to respond to the intervention.
| Ancillary analyses
Of the 10 intervention subjects (32%) who found an improvement for at least one odour, five of the 10 had improved at 15 minutes with three reaching peak improvement at 15 minutes. For the other seven, peak improvement was reached at 30 minutes for five subjects, 45 minutes for one and 60 minutes for a another one (two examples are provided in Figures 3 and 4) . The average time for subjects to register 2 logarithmic dilution improvements in threshold was 38.7 minutes with the average time to maximum effect 47.4 minutes and the average duration 54 minutes. In most patients, the threshold levels for all odours had returned to baseline (AE1 threshold step) by the end of the 2-hour test period. Fourteen patients did not continue repeat threshold testing beyond 60 minutes due to a lack of response following the intervention. it would make timing of use of the spray practicable. It is notable that amongst those who responded, the effect was not universal across all four odours.
T A B L E 1 Demographic and baseline information
| Limitations
Whilst a positive effect was seen in 10 participants in the intervention arm, there remained 21 participants who perceived no discernible effect on their olfactory performance, and therefore, this cannot be seen as a panacea for all patients with NCODs. The sample size here is too small to allow for a subgroup analysis by diagnosis; however, there does not appear to have been a specific clustering of responders within one subgroup (PVOL), suggesting that more than one group may stand to benefit from this intervention (Table 5 ). Therefore, although the diagnostic group with the greatest number of responders is the PVOL group, it is notable that patients in the idiopathic group also responded. It is however possible that the idiopathic cases are indeed post-viral in nature even if lacking in the temporal relation to an upper respiratory tract infection. It should also be noted that the different subgroups may well reflect different sites of pathology within the olfactory apparatus (ie, olfactory epithelium/receptors in PVOL and olfactory nerves/secondary cortex in PTOL), so future studies will need to power for individual subgroups. Seven participants were tested with mercaptan rather than 1-butanol and so these data were not used in the analysis, but we do not believe this detracts from the findings presented here.
The trial as reported here is designed to assess the use of sodium citrate in a single application for NCODs. However, to be effective as a treatment for patients, this positive effect would need to be repeatable on subsequent applications and to be tolerated by patients. In practice, due to the short duration of effect, this would involve patients having to apply the spray to their noses at frequent intervals such as mealtimes; however, feedback from patient panels at our institution favours this possibility. Other concentrations of sodium citrate could have been considered; however, we decided to select the highest concentration currently available to reduce the sample size needed for this trial. As our primary outcome, we used olfactory threshold tests that only assessed four odours, and it is possible that testing a wider array of odours might have enabled more positive responses, albeit that practically speaking this would have been difficult to achieve with 15-minute intervals for threshold tests, but achievable with an identification test.
| Interpretation
The data presented here do not thrust sodium citrate spray forwards as a therapeutic option immediately, but do suggest merit in undertaking further multicentre trials to evaluate this intervention further.
Seen in conjunction with the previous trial 8 of sodium citrate in olfactory disorders, the results do not appear to be spurious. In fact, a recent trial at the Dresden Smell & Taste Clinic performed using one nostril as the test site and the contralateral one as a control has shown benefit in the PVOL diagnostic group too. 16 
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